I recently had the privilege of co-presenting on a panel at RISE West in San Diego titled “RA Litigation Today: What Lawyers Say About Risk, Enforcement, and Exposure.” I sat alongside Brian Boynton of WilmerHale, a former senior official at the U.S. Department of Justice, and Ari Yampolsky of Whistleblower Partners, a firm that represents qui tam relators. Our 60-minute discussion covered the rapidly evolving landscape of False Claims Act (FCA) enforcement in the Medicare Advantage (MA) risk adjustment space. What follows are three critical themes that every compliance officer, in-house counsel, and healthcare attorney should be tracking.
A Wave of Eight- and Nine-Figure Settlements
The sheer volume and magnitude of recent FCA settlements involving MA risk adjustment were a central focus of the panel. In January 2026, Kaiser affiliates agreed to pay $556 million to resolve allegations that they pressured physicians to add diagnoses through retrospective addenda after patient visits, linking bonuses to “aggressive” diagnosis-coding goals. In March 2026, Aetna settled for $117.7 million over allegations of “one-way” chart reviews that added diagnosis codes but failed to delete or withdraw unsupported ones, including morbid obesity codes allegedly applied to patients whose body mass index (BMI) measurements fell below the clinical threshold.
The Matrix/HealthFair settlement, $56.5 million in total ($36.5 million from Matrix, $5 million from HealthFair, and $15 million from alleged orchestrator Shahriah Ekbatani individually), targeted an in-home assessment vendor accused of marketing its services to Medicare Advantage Organizations (MAOs) based on the HCC and RAF “lift” its assessments would generate. Critically, the nurse practitioners involved allegedly diagnosed but did not treat the patients. The Seoul Medical Group settlement ($58.74 million, plus $1.76 million from Dr. Cha individually and $2.35 million from Renaissance Imaging) involved allegations of fabricated spinal diagnosis codes and falsified radiology reports. Most recently, in August 2026, The Villages Health System LLC (The Villages) settled for $541.5 million over allegations of retrospective “sprints” that inserted diagnosis codes into patient records months or even years after visits, including amendments not initiated by the rendering providers.
The collective message is clear: the government is investing significant resources in MA risk adjustment enforcement, and the financial stakes for organizations facing FCA scrutiny can be substantial.
Downstream Providers and Individuals Are Squarely in the Crosshairs
Perhaps the most consequential theme from our discussion was the government’s unmistakable pivot toward targeting downstream entities and individuals, not just MAOs. The traditional enforcement model focused primarily on the health plans submitting risk adjustment data to the Centers for Medicare & Medicaid Services (CMS). That paradigm has shifted.
In the Matrix settlement, Ekbatani paid $15 million individually, and the settlement agreement explicitly did not release “any current or former officer, director, employee, or agent” from liability. Matrix was required to cooperate with the government and make employees available for interviews and testimony. In Seoul, Dr. Cha paid $1.76 million personally, and Renaissance Imaging, a radiology group alleged to have helped fabricate supporting records, paid $2.35 million, illustrating the potential for third-party conspirator liability.
This enforcement posture was further reinforced by the U.S. Department of Health and Human Services Office of Inspector General’s (HHS-OIG) 2026 Medicare Advantage Industry Compliance Program Guidance, the first such guidance since 1999, which specifically addresses “conduct by MAOs, providers, and others involved in the risk adjustment process.” The message to downstream entities is clear: this guidance is directed at them, too. Corporate settlements also do not necessarily resolve potential liability for individuals. Officers, directors, compliance officers, and medical directors may face individual exposure depending on their conduct, including potential FCA liability, criminal enforcement, exclusion from federal healthcare programs, and qui tam litigation.
Self-Disclosure: Not a Panacea, but a Powerful Tool
The Villages Health case offers what may be one of the most instructive data points for compliance professionals weighing whether to self-disclose potential risk adjustment issues. The Villages self-disclosed to HHS-OIG on December 27, 2024, via the Health Care Fraud Self-Disclosure Protocol. Its settlement amount of $541.5 million equaled exactly 1.5 times the $361 million it received from MAOs, a significant discount from the FCA’s statutory treble-damages ceiling of three times the actual damages. The DOJ’s press release expressly stated that the self-disclosure and cooperation “were important factors in resolving this matter,” and The Villages received credit under Justice Manual § 4-4.112 for its disclosure, cooperation, and remediation efforts.
By comparison, in Seoul and Matrix individuals paid millions in personal liability, and settlement agreements preserved the government’s right to pursue additional individuals. The Villages settlement names no individuals, despite the alleged conduct resulting in a substantially larger settlement. Self-disclosure did not prevent The Villages from filing Chapter 11 bankruptcy in July 2025; $541.5 million is still a substantial sum. But the comparison strongly suggests it meaningfully mitigated total exposure and, critically, individual risk.
For compliance officers making the case to their boards, these data points are concrete evidence: self-disclosure is not painless, but it may be the most effective tool for mitigating the worst outcomes.
Conclusion
The pace and scale of MA risk adjustment enforcement have accelerated dramatically. The government’s enforcement lens has widened well beyond MAOs to encompass the entire downstream ecosystem, including providers, vendors, independent practice associations (IPAs), management services organizations (MSOs), and the individuals who lead them. Organizations and individuals should be evaluating their risk adjustment compliance programs now. They should also understand that self-disclosure, while far from costless, may provide an important avenue for mitigating potential exposure when significant compliance concerns are identified.
How Frier Levitt Can Help
Frier Levitt advises downstream risk-bearing providers and other entities, such as vendors, involved in risk adjustment on both commercial and FCA-related matters. Our attorneys help clients assess potential risk, strengthen compliance programs, respond to government scrutiny, and evaluate appropriate corrective action when issues arise. If your organization has identified potential Medicare Advantage risk adjustment concerns or is facing an investigation or enforcement action, contact Frier Levitt to discuss your legal and compliance options.
